BMS-986165, also known as deucravacitinib, is a first-in-class, oral, selective tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of adults with moderate-to-severe plaque psoriasis. By binding… Read more


























BMS-986165, also known as deucravacitinib, is a first-in-class, oral, selective tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of adults with moderate-to-severe plaque psoriasis. By binding to the regulatory domain of TYK2, it inhibits the signaling pathways of IL-23, IL-12, and Type I interferons, effectively modulating immune responses. Pharmaceutical laboratories require high-quality reference standards, including associated impurities, metabolites, and stable isotope-labelled compounds, to support rigorous quality control and regulatory compliance for this active pharmaceutical ingredient. These materials are essential for accurate impurity profiling and analytical method validation, ensuring the reliability of drug testing protocols. Stable isotope-labelled versions serve as critical internal standards for mass spectrometry-based bioanalytical studies, allowing for precise quantification of the drug and its metabolites in complex biological matrices. Utilizing these analytical benchmarks facilitates consistent performance in research, method development, and clinical evaluation throughout the pharmaceutical product lifecycle.